Leaderboards/Antibody Drug Conjugates

Antibody Drug Conjugates

Last updated May 19, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Aditya Bardia
University of California, Los Angeles
375 cit.
2
D. Ross Camidge
University of Colorado Cancer Center
372 cit.
3
Buwei Huang
University of Washington
348 cit.
4
Yuxiang Ma
Sun Yat-sen University
312 cit.
5
Oscar P. B. Wiklander
Karolinska University Hospital
293 cit.
6
Jacob Sands
Dana-Farber Cancer Institute
264 cit.
7
Binghe Xu
Chinese Academy of Medical Sciences & Peking Union Medical College
243 cit.
8
Francisco Guarner
Hospital Quirón Teknon
174 cit.
9
Li-Chung Tsao
Duke University
168 cit.
10
Antoine G. van der Heijden
Unknown
140 cit.

Rising Stars Papers

1
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
Journal of Clinical Oncology|2024
124 cit.
2
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
Journal of Clinical Oncology|2024
123 cit.
3
Designed endocytosis-inducing proteins degrade targets and amplify signals
Nature|2024
115 cit.
4
Antibody-displaying extracellular vesicles for targeted cancer therapy
Nature Biomedical Engineering|2024
116 cit.
5
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
Journal of Clinical Oncology|2025
87 cit.
6
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
Nature Medicine|2025
65 cit.
7
World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics
Journal of Clinical Gastroenterology|2024
173 cit.
8
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
Nature Communications|2025
83 cit.
9
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines
European Urology|2025
139 cit.
10
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
Annals of Oncology|2025
68 cit.

Rising Stars Reagents

Coming soon

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Jung‐Yun Lee
Yonsei University
963 cit.
2
Pasi A. Jänne
Dana-Farber Cancer Institute
290 cit.
3
Funda Meric‐Bernstam
The University of Texas MD Anderson Cancer Center
222 cit.
4
Sara A. Hurvitz
Fred Hutch Cancer Center
218 cit.
5
Liang Cheng
John Brown University
209 cit.
6
Rebecca S. Heist
Massachusetts General Hospital
159 cit.
7
Markus Eckstein
Friedrich-Alexander-Universität Erlangen-Nürnberg
156 cit.
8
Toon Van Gorp
Inserm
125 cit.
9
Kan Yonemori
Tokyo National Hospital
115 cit.
10
Yohann Loriot
Université Paris-Saclay
108 cit.

Emerging Leaders Papers

1
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Journal of Clinical Oncology|2023
879 cit.
2
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
Journal of Clinical Oncology|2024
148 cit.
3
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
Journal of Clinical Oncology|2024
145 cit.
4
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Journal of Clinical Oncology|2023
216 cit.
5
Advances in diagnosis and treatment of bladder cancer
BMJ|2024
417 cit.
6
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01
Journal of Clinical Oncology|2023
159 cit.
7
<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer
Journal of Clinical Oncology|2024
104 cit.
8
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
New England Journal of Medicine|2023
376 cit.
9
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial
Journal of Clinical Oncology|2023
115 cit.
10
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3
Journal of Clinical Oncology|2024
72 cit.

Emerging Leaders Reagents

Coming soon

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Kenneth A. Dawson
University College Dublin
4.5k cit.
2
Robert Chen
The University of Texas MD Anderson Cancer Center
4.5k cit.
3
William Mallet
Unknown
4k cit.
4
Kim T. Blackwell
Duke Medical Center
3.8k cit.
5
Peter D. Senter
Seagen (United States)
3.5k cit.
6
Zhibo Liu
Peking University
3.2k cit.
7
Jagath R. Junutula
Snap (United States)
3k cit.
8
Andrei R. Shustov
Unknown
3k cit.
9
Simon C. Ling
Baylor College of Medicine
2.8k cit.
10
Jung‐Yun Lee
Yonsei University
2.6k cit.

All-Time Leaders Papers

1
Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface
Nature Nanotechnology|2013
1.8k cit.
2
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Journal of Clinical Oncology|2012
1.5k cit.
3
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Nature Biotechnology|2008
1.3k cit.
4
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
New England Journal of Medicine|2012
3.8k cit.
5
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Nature Biotechnology|2003
1.2k cit.
6
A bioorthogonal system reveals antitumour immune function of pyroptosis
Nature|2020
1.1k cit.
7
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
Nature Biotechnology|2012
990 cit.
8
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Journal of Clinical Oncology|2012
987 cit.
9
Diagnosis and Management of Autoimmune Hepatitis
Hepatology|2010
1.4k cit.
10
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Journal of Clinical Oncology|2023
879 cit.

All-Time Leaders Reagents

Coming soon

Indexing Antibody Drug Conjugates Reagents

Citation data for reagents in this field is currently compiling.